Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Acromegaly is a chronic systemic disease with many complications and is associated with
increased mortality when not adequately treated. Substantial advances in acromegaly …

Somatostatin (SST), an inhibitory polypeptide with two biologically active forms SST14 and
SST28, inhibits GH, prolactin (PRL), TSH, and ACTH secretion in the anterior pituitary gland …

Objective Clinically nonfunctioning pituitary adenoma (NFPA) remains the only pituitary
tumor subtype for which no effective medical therapy is available or recommended. We …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Non-functioning pituitary neuroendocrine tumors do not cause endocrine symptoms related
to hypersecretion of adenohypophyseal hormones and are clinically characterized by …

Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and
non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release …

Objective: Pituitary adenomas are the third most common central nervous system tumors
and arise from the anterior pituitary within the pituitary fossa. Methods: Literature review and …

Context: Transsphenoidal surgery is considered first-line therapy for acromegaly; however,
there is often a need for adjunctive therapy. Somatostatin analogs (SSA) have greatly …